Patents by Inventor Karen Thibaudeau
Karen Thibaudeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11291711Abstract: Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1%, and more particularly by at least 10%, of the normal plasminogen activity and for maintaining the plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-II plasminogen-deficiency or an acquired deficiency.Type: GrantFiled: November 3, 2016Date of Patent: April 5, 2022Assignee: PROMETIC BIOTHERAPEUTICS, INC.Inventors: Martin Robitaille, Karen Thibaudeau, Pierre Laurin, Stacy Plum
-
Publication number: 20190231854Abstract: Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1%, and more particularly by at least about 10%, of the normal plasminogen activity and for maintaining said increased plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-II plasminogen-deficiency or an acquired deficiency.Type: ApplicationFiled: November 3, 2016Publication date: August 1, 2019Inventors: Martin ROBITAILLE, Karen THIBAUDEAU, Pierre LAURIN, Stacy PLUM
-
Patent number: 8039432Abstract: The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.Type: GrantFiled: November 9, 2006Date of Patent: October 18, 2011Assignee: Conjuchem, LLCInventors: Dominique P. Bridon, Jean-Paul Castaigne, Karen Thibaudeau
-
Patent number: 7982018Abstract: The present invention relates to compounds comprising modified corticotrophin releasing factor peptide and specifically urocortin and urocortin-related peptides, modified derivatives thereof, and conjugates of such modified peptides and derivatives to serum components, preferably serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group, which is covalently attached to a modified peptide or derivative, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide or derivative to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention preferably exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and preferably exhibit increased biological activity compared to the unconjugated peptides.Type: GrantFiled: October 16, 2007Date of Patent: July 19, 2011Assignee: Conjuchem, LLCInventors: Thomas R. Ulich, Jean-Philippe Estradier, Karen Thibaudeau
-
Publication number: 20110071082Abstract: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.Type: ApplicationFiled: April 13, 2010Publication date: March 24, 2011Inventors: Dominique P. Bridon, Michele Rasamoelisolo, Karen Thibaudeau, Xicai Huang, Richard Beliveau
-
Patent number: 7906482Abstract: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.Type: GrantFiled: October 24, 2007Date of Patent: March 15, 2011Assignee: Advanced Diagnostics and DiscoveryInventors: Dominique P. Bridon, Roger Leger, Xicai Huang, Karen Thibaudeau, Martin Robitaille, Peter G. Milner
-
Patent number: 7741286Abstract: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.Type: GrantFiled: February 8, 2006Date of Patent: June 22, 2010Assignee: ConjuChem Biotechnologies Inc.Inventors: Dominique P. Bridon, Michele Rasamoelisolo, Karen Thibaudeau, Xicai Huang, Richard Beliveau
-
Patent number: 7737251Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.Type: GrantFiled: December 23, 2005Date of Patent: June 15, 2010Assignee: ConjuChem Biotechnologies Inc.Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Leger, Martin Robitaille, Karen Thibaudeau, Julie Carette
-
Publication number: 20090312259Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.Type: ApplicationFiled: July 19, 2009Publication date: December 17, 2009Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Leger, Martin Robitaille, Karen Thibaudeau, Julie Carette
-
Patent number: 7601691Abstract: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.Type: GrantFiled: February 25, 2005Date of Patent: October 13, 2009Assignee: Conjuchem Biotechnologies Inc.Inventors: Dominique P. Bridon, Roger Leger, Xicai Huang, Karen Thibaudeau, Martin Robitaille, Peter G. Milner
-
Publication number: 20090175821Abstract: A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.Type: ApplicationFiled: October 31, 2007Publication date: July 9, 2009Inventors: Dominique P. Bridon, Alan M. Ezrin, Peter G. Milner, Darren L. Holmes, Karen Thibaudeau
-
Publication number: 20090099074Abstract: The present disclosure relates to a conjugate comprising a PYY peptide or a functional derivative thereof which is coupled to a reactive group. Such a reactive group reacts with albumin so as to form a stable covalent bond therewith. The disclosure further provides methods of reducing water or food intake and reducing food intake between meals by administering such conjugates.Type: ApplicationFiled: December 27, 2007Publication date: April 16, 2009Applicant: CONJUCHEM BIOTECHNOLOGIES INC.Inventors: Dominique P. Bridon, Karen Thibaudeau, Alastair Ferguson, Denis Richard
-
Publication number: 20090054332Abstract: The present invention relates to compounds comprising modified thrombopoietin peptides and conjugates of such modified peptides to serum components, typically serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group or a residue of a reactive group, which is covalently attached to a modified peptide, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention typically exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and typically exhibit increased biological activity compared to the unconjugated peptides.Type: ApplicationFiled: June 21, 2008Publication date: February 26, 2009Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: Jean-Philippe Estradier, Martin Robitaille, Karen Thibaudeau, Dominique P. Bridon, Xicai Huang, Omar Quraishi, Nathalie Bousquet-Gagnon
-
Publication number: 20080194486Abstract: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.Type: ApplicationFiled: October 24, 2007Publication date: August 14, 2008Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: Dominique P. Bridon, Roger Leger, Xicai Huang, Karen Thibaudeau, Martin Robitaille, Peter G. Milner
-
Publication number: 20080167231Abstract: The present invention relates to compounds comprising modified corticotrophin releasing factor peptide and specifically urocortin and urocortin-related peptides, modified derivatives thereof, and conjugates of such modified peptides and derivatives to serum components, preferably serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group, which is covalently attached to a modified peptide or derivative, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide or derivative to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention preferably exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and preferably exhibit increased biological activity compared to the unconjugated peptides.Type: ApplicationFiled: October 16, 2007Publication date: July 10, 2008Inventors: Thomas R. Ulich, Jean-Philippe Estradier, Karen Thibaudeau
-
Publication number: 20070207958Abstract: The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.Type: ApplicationFiled: November 9, 2006Publication date: September 6, 2007Inventors: Dominique Bridon, Jean-Paul Castaigne, Karen Thibaudeau
-
Patent number: 7256253Abstract: A secretin or secretin derivative protected against peptidase activity. The secretin or derivative comprises a peptidic sequence and a reactive group selected from the group consisting of succinimidyl and maleimido groups capable of reacting with an amino group, hydroxyl group or thiol group on a blood component to form a stable covalent bond. The reactive group is attached at a position along the peptidic sequence that provides, when conjugated to a blood component, a higher stability against peptidase degradation than the unconjugated secretin or derivative, and therefore an increased maintenance of the therapeutic activity compared to the unconjugated secretin or derivative. Such a compound is thus effective to provide a source of secretin having a high stability against peptidases. A method for synthesizing such a compound is also described.Type: GrantFiled: February 25, 2005Date of Patent: August 14, 2007Assignee: ConjuChem Biotechnologies Inc.Inventors: Dominique P. Bridon, Alan M. Ezrin, Peter G. Milner, Darren L. Holmes, Karen Thibaudeau
-
Patent number: 7144854Abstract: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.Type: GrantFiled: September 7, 2000Date of Patent: December 5, 2006Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Michele Rasamoelisolo, Karen Thibaudeau, Xicai Huang, Richard Beliveau
-
Publication number: 20060217304Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.Type: ApplicationFiled: December 23, 2005Publication date: September 28, 2006Inventors: Dominique Bridon, Nissab Boudjellab, Roger Leger, Martin Robitaille, Karen Thibaudeau, Julie Carette
-
Patent number: 7112567Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.Type: GrantFiled: February 15, 2002Date of Patent: September 26, 2006Assignee: ConjuChem Inc.Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Léger, Martin Robitaille, Karen Thibaudeau, Julie Carette